CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy.

Abstract

The study by Kelly and colleagues, published in the September 1, 2003, issue of Clinical Cancer Research, established the safety and biologic activity of the first-in-class histone deacetylase inhibitor, vorinostat, which was administered intravenously. Subsequent studies led to the development of oral vorinostat and the regulatory approval of vorinostat for cutaneous T-cell lymphomas, which opened the door for the next generation of inhibitors.

• Authors: Wm Kevin Kelly, Paul Marks, Victoria M Richon
• Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 21 Issue 10 Pg. 2198-200 (May 15 2015) ISSN: 1557-3265 [Electronic] United States
• PMID: 25979925 (Publication Type: Journal Article, Comment)
• Copyright: ©2015 American Association for Cancer Research.

Chemical References

• Histone Deacetylase Inhibitors
• Hydroxamic Acids

Topics

• Female
• Hematologic Neoplasms (drug therapy)
• Histone Deacetylase Inhibitors
• Humans
• Hydroxamic Acids (administration & dosage)
• Male